

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Porphyromonas Gingivalis A Multitasking Pathogen.

Roopa Yadahalli*, Supriya Kheur, and Aanchal Adwani.

Department of Oral Pathology and Microbiology, Dr.D.Y.PatilVidyapeeth's, Dr. D.Y.Patil Dental College and Hospital, Pimpri, Pune-18, Maharashtra, India.

ABSTRACT

Porphyromonas gingivalis is a ubiquitous organism primarily responsible for causing chronic generalized periodontitis. The inflammatory properties of Porphyromonas gingivalis are more nuanced, and the organism can exhibit both pro- and anti-inflammatory properties, depending on the context. The end toxin and gingipains released by the bacteria sets up an inflammatory stage which is responsible for various distant systemic pathologies in human body. Porphyromonasgingivalis has evolved several mechanisms to evade host immune system by invasion of host cells and disrupting signaling pathways by cytokine and receptor degradation. This paper overviews the various systemic diseases caused from the infection of Porphyromonas gingivalis in the periodontal apparatus in the oral cavity.

Keywords: Porphyromonas gingivalis, periodontal disease, systemic diseases.

**Corresponding author*

INTRODUCTION

Porphyromonas (formerly Bacteroides) gingivalis, a Gram-negative anaerobe, has a diverse range of virulence factors. The introduction of Porphyromonas gingivalis (*P. gingivalis*) to the medical community was by Nisengard and Newman [1]. Porphyromonas is derived from Greek word porphyries which means purple and monas which means unit. *P. gingivalis* is a major habitat of sub gingival sulks. It is a non-motile, asaccharolytic, Gram-negative bacteria which is an obligate anaerobe. On culture with blood agar it shows black-pigmented colonies. [2].

This opportunistic pathogen of oral mucosa known to be involved in periodontitis may also have a vital role in mediating the progression of several multifactorial and obviously unrelated chronic systemic diseases. The host and the micro biota of the oral cavity normally exist in a stable immunoinflammatory relationship. *P. gingivalis* however has the ability to disturb this balanced state, leading to a dysbiotic host–microbial interaction [3]. The periodontal blood vessels undergo proliferation and enlargement in inflammatory conditions such as gingivitis and chronic periodontitis, which provides a larger surface area that in turn, facilitates the entry of microorganisms into the circulation which may in turn lead to lodgment of these bacteria into different target organs, resulting in infections [4]. It has been recognized as a risk element for many systemic diseases such as coronary heart disease, pulmonary infections, diabetes mellitus and pre-term to low birth weight deliveries [5]. Several studies have validated that there exists a considerable relationship between periodontitis and oral squamous cell carcinoma (OSCC) and or digestive cancer [6]. It was also recovered from several cases of appendicitis and peritonitis in adults and children. In the oral cavity other than periodontitis it was found in other oral infections, such as infected root canals, peritonsillar abscesses, and odontogenic abscesses [7]. A good understanding of the path physiological mechanism of *p.gingivalis* therefore becomes necessary. Hence, the purpose of this review is to emphasize the pit fall that are unconnected to the connectivity between *P.gingivalis* and other local and systemic morbidities.

VIRULENCE FACTORS

GINGIPAIN:

They are the known factors expressed in tissue damage in periodontitis. *P.gingivalis* secretes Arg-gingipain (Rgp) and lys-gingipain (Kgp). Tissue damage by gingipains was from the degradation of matrix metalloproteinase, collagen, and fibronectin. They have the propensity to cleave subclass 1 and 3 IgG antibodies. In higher concentration of *P. gingivalis* gingipains trigger proinflammatory cytokines response such as IL-1 β , IL-2, IL-6, TNF- α and IL-8 [8].

CAPSULAR POLYSACCHARIDE

The capsular polysaccharide (CPS) when present down regulates pro-inflammatory cytokines production IL-1 β , IL-6, IL-8, and TNF- α , indicating host evasion responses [9]. The other studies have found that the CPS elicits host immune responses like polymorph nuclear neutrophils migration and time and dose dependent expression of cell migration chemokines like MCP-1, KC, MIP-2 and RANTES [10].

FIMBRIAE

Virulence factor of *P. gingivalis* is strongly associated with its fimbriae. They have been involved to be the main factors in cell adhesion, invasion, colonization and invading membrane vesicles into host cells [11]. By binding to cellular α 5 β 1 integrins, they mediate adherence and impairment of the homeostatic controls of host cells [12]. These fimbriae are incidental with altering β 2 integrins adhesive activity which further were up taken by monocytes using the CD14/TLR2/PI3K signaling complex, and may promote to intracellular evasion by *P. gingivalis* [12].

P.GINGIVALIS AND CANCER:

Several epidemiological studies have shown that *P. gingivalis* is in association with cancers like oral squalors cell carcinoma (OSCC), as it has the ability to spread systemically, and also helps in cell survival and proliferation [13,14]. *P. gingivalis* is now known to be a possible independent risk factor that increases the

probability of or digestive cancer death. Many studies have correlated higher levels of antibodies to *P. gingivalis*, in periodontal diseases with an increased risk of pancreatic cancer [15].

The study by Nagy KN et al [16] showed that the level of *P. gingivalis* was higher on the surfaces of OSCCs than that of the adjacent normal mucosa. *P. gingivalis* antibodies detected by immunohistochemistry within gingival carcinomas showed greater intensity of staining. Studies have also shown that infection with both *P. gingivalis* and *Fusobacterium nucleate* (*F.nucleatum*) helps in advancement of the tumor in oral-specific chemical carcinogenesis mouse model [17]. The possible mechanisms of *P. gingivalis* that help in the progression of OSCC include evasion of immune system, inhibition of apoptosis, carcinogen conversion, MMP-9 induction and dysbiosis of the oral micro biome [18].

The possible molecular basis for carcinogenesis mediated by *P. gingivalis* can be explained in different aspects. Chronic inflammation has been shown to be associated with the development of cancer. Prolonged IL-6 signaling and STAT3 activity helps in tumor progression [19, 20]. *P. gingivalis* increases the production of IL-6 in epithelial cells activating JAK2 and GSK3 β pathways [20, 21]. Secondly, *P. gingivalis* secretes nucleoside diphosphate kinase (NDK) which inhibits P2X7 receptor activation by ATP thereby reducing IL-1 β production from epithelial cells. This mechanism also suppresses apoptosis by degradation of ATP by NDK thereby promoting tumor genesis [22]. Thirdly, *P. gingivalis* inhibits apoptosis of epithelial cells by different mechanisms which include activation of Jak1/Akt/Stat3, increasing the Bcl2: Bax ratio (Bcl2 being antiapoptotic and Bax being proapoptotic), inhibiting the release of cytochrome c which helps in apoptosis, and the activation of downstream caspases [23]. *P. gingivalis* also cause upregulation of micro-RNAs like miR-203, which inhibit apoptosis in gingival epithelial cells [24]. Lastly, *P. gingivalis* also enhances cellular migration in OSCC cells by activation of various pathways like ERK1/2-Ets1, p38/HSP27, and PAR2/NF- κ B pathways which induce expression of pro-matrix metalloproteinase (MMP)-9. Apart from the above mentioned mechanisms another possible *P. gingivalis* mediated carcinogenesis mechanism is the metabolism of potential carcinogens [25]. For example, *P. gingivalis* causes conversion of ethanol to acetaldehyde, which is capable of inducing DNA damage, mutagenesis and hyper proliferation of the epithelium. This could also help in explaining the epidemiological evidence of association between heavy drinking and development of some cancers [26].

P.GINGIVALISAND CARDIOVASCULAR DISEASES:

Cardiovascular diseases (CVD) account for 29% of deaths worldwide [27]. Various studies have demonstrated the presence of oral micro biota in atherosclerotic plaques. In a study conducted by Ford PJ et al [28], *P. gingivalis* was found to be present in 100% of atherosclerotic plaques using real-time PCR [28]. By interacting with the endothelial surface, *P. gingivalis* induces proliferation of smooth-cell and hence causes impairment of the vasomotor function of endothelial cells [29]. On investigation of carotid athermanous plaques, Cairo Fet al [30] detected DNA of *P. gingivalis* in 37%, along with other oral microorganisms from carotid atheroma patients [30]. *P. gingivalis* activates a phagocytic cell which is triggered by bacterial LPS as a result of which levels of PGE₂, IL-1 β , and TNF- α increase. The macrophages can then convert into foam cells and induce the formation of proinflammatory cytokines. These cytokines are responsible for endothelial dysfunction [29].

Other studies have also shown that oral micro biome like *Streptococcus sanguis* and *P. gingivalis* contribute to development of thrombus by inducing platelet aggregation [31]. A study by Deshpande RG et al [32] explained that *P. gingivalis* has the ability to actively attach and entre the endothelial cells of fetal bovine heart, bovine aortic, and human umbilical vein [32]. *P. gingivalis* also releases proteolytic enzymes like gingipains R in large amounts. These enzymes then promote thrombus formation by causing activation of factor X, prothrombin, and protein C and subsequently leading to intravascular clot formation. Periodontitis stimulates to produce C-reactive protein (CRP) by liver, which will be deposited on severed blood vessels. CRP then binds to the injured cells and fixes complement, which will activate phagocytes thereby contributing to atheroma formation, by the release of nitric oxide [33].

P. GINGIVALIS AND DIABETES MELLITUS:

Diabetes mellitus and periodontitis share a unique interrelation. Studies have reported that diabetes mellitus may flare-up the periodontal disease condition. On the contrary, recent researches have also revealed that periodontal diseases can be a risk factor for development of insulin resistance and diabetes mellitus [34]. The study by Padmalatha G et al [35] showed high glucose levels in type II DM patients which lead to the development of periodontogenic flora due to reduced oxygen production and defense cells. Hence, diabetic patients have an increased susceptibility for more severe periodontal disease due to increased prevalence of *P. gingivalis* [35].

Ishikawa M et al [36] demonstrated that *P. gingivalis* can translocate to liver from the oral cavity and incorporates into hepatocytes. Insulin stimulation in hepatocytes normally cause increase in IRS-1 and Akt/GSK-3 β phosphorylation, preceded by GS activation. Activated GS further increases glycogen synthesis and lower level of blood glucose implying that the existence of *P. gingivalis* in hepatic cells prevents this insulin signaling pathway resulting in decreased glycogen synthesis [36]. Study was conducted by Ishikawa M et al by inducing periodontitis in 4 week female Balb/c mice by inoculating SNAP26b-tagged *P. gingivalis* (SNAP-P.g.) into the oral cavity. This SNAP-P.g. was found from the liver of these mice using nested PCR analysis. There was an increased blood glucose level in these mice which inclined towards SNAP-P.g. translocation to the liver from the oral cavity. In same study SNAP-P.g. was also internalized in the human hepatoma cell line HepG2. They found that SNAP-P.g. put down the insulin-induced glycogen synthesis in HepG2 cells suggesting that *P. gingivalis* translocated to the hepatic cells from the periodontal apparatus may contribute to the advancement of diabetes mellitus by affecting hepatic glycogenesis [36].

Study by Taylor et al [37] showed that severe periodontitis caused increase in HbA1c levels in type 2 diabetes mellitus. Studies have also shown that periodontitis raises the incidence of type 2 diabetes mellitus among non-diabetics and that periodontal health is also related with insulin resistance [37,38]. Study by Makiura et al [39] showed that subjects with increased HbA1c values, the *P. gingivalis* was more frequently detected after periodontal therapy than in subjects with lower values of HbA1c. Moreover, in patients with increased HbA1c, *P. gingivalis* with type II fimbriae was found, while in patients with reduced HbA1c values did not show these type II clones. This result suggested that high glycemic value in diabetes is affected by presence of *P. gingivalis*, with type II fimbriae clones, in periodontal pockets [39]. In diabetic mice, *P. gingivalis* inoculation resulted in tissue injury with significantly higher fibroblast apoptosis as compared to non-diabetic mice. This showed that diabetes can also alter the repair capacity in inflamed periodontal tissues [40].

P. GINGIVALIS AND PRETERM LOW-BIRTH-WEIGHT:

P. gingivalis was found in amniotic fluid with premature labor; however, a definitive role of this bacterium in premature delivery is yet to be confirmed [41]. Recurrent colonization of oral bacteria including *P. gingivalis* is common following the dental procedures, and even been seen with periodontitis during simple mastication, thus allowing *P. gingivalis* to spread through hematogenous route and reach the placenta [42].

Studies have shown that certain bacteria like *Bacteroides forsythus* (*B. forsythias*), *P. gingivalis*, *Actinobaculum actinomycetemcomitans* (*A. actinomycetemcomitans*) and *Treponema denticola* (*T. denticola*), that are known to be integrated in mature plaque and progressive periodontitis. These bacteria are found in high titer in mothers of preterm low-birth-weight infants than in control mothers. This data suggested that oral microbial burden is associated with preterm birth and low birth weight (PLBW) [43]. Study by Katz J et al [44] also showed that *P. gingivalis* may enter the placental tissue and be partly responsible for preterm delivery [44]. The growth of anaerobic *P. gingivalis* takes place in the first 10-12 weeks of gestation as the placenta in this stage is in a state of physiological hypoxia [45]. Study by Hasegawa-Nakamura K [46] showed the presence of *P. gingivalis* in chorion of high-risk pregnant women, and bacterial lip polysaccharide induces interleukin-6 and interleukin-8 production via TLR-2 in chorion-derived cells [46]. A study showed that women with increased levels of serum IgG against *P. gingivalis* had more possibility of giving birth to a PLBW infant compared to women with lower levels of IgG against *P. gingivalis* [47].

P. GINGIVALIS AND RHEUMATOID ARTHRITIS

Many researchers have shown the link between periodontitis and rheumatoid arthritis (RA). Periodontitis and RA, both, occur due to a disbalance between pro- and anti-inflammatory cytokines. The early treatment was tooth eradication. TNF- α , a proinflammatory cytokine, is common in both diseases regulating a cascade of inflammatory events [48]. *P. gingivalis* even detected in synovial fluid. *P. gingivalis* causes proteolytic cleavage at Arg-X peptide bonds by arginine gingipains resulting in citrullination of host peptides and inducing autoimmune responses in RA. Autoimmune responses in subjects with RA may also be triggered due to the heat shock proteins (HSPs) of *P. gingivalis*. Studies have shown that treatment of periodontal disease along with routine RA treatment can further improve overall health of RA patients [49]. By the generation of citrullinated host peptides, *P. gingivalis* also causes citrullination of carboxy-terminal arginines by bacterial peptidylarginine deiminase [49]. *P. gingivalis* possesses a number of endogenous citrullinated proteins that are absent in other oral bacteria [50]. The importance of citrullination in RA is given by the expression of citrullinated autoantigens in synovial fluid [51]. Thus in case of *P. gingivalis* infection, due to its ability to citrullinate host peptides may be the cause in development of RA.

Increased antibody titres against *P. gingivalis* are seen in RA patients and even tend to be seen along with disease-specific autoimmunity. Association of its titers with RA autoantibody and CRP concentrations were found to be higher level in periodontitis. This shows that *P. gingivalis* infection has a role in progression of RA [52].

P. gingivalis particularly decomposes lysine and arginine; the IgG3 CH2 and CH3 domains processed by *P. gingivalis* proteinase become powerful targets for the rheumatoid factor produced by rheumatoid cells. The IgG levels of *P. gingivalis*, *Prevotella intermedia*, *Prevotellamelaninogenica* and *B. forsythias* were found to be noticeably at high level in RA patients that with those of the control patients [53]. Hence, careful screening of RA patients and appropriate treatment of their periodontal condition is necessary.

P. GINGIVALIS AND RESPIRATORY DISEASES:

Several mechanisms explaining how the oral bacteria are play role in the pathogenesis of respiratory tract infection have been proposed. One of these mechanisms involves aspiration of oral bacteria like *P. gingivalis*, *A. actinomycetemcomitans* etc. into the lungs which are then responsible to cause the infections; the enzymes associated with periodontal disease that are present in the saliva can cause modification of mucosal surfaces thereby promoting adherence and colonization of respiratory pathogens following which they are carried into the lungs; these enzymes also cause destruction of salivary pellicle on the bacteria and interfere with their clearance from the mucosa; the cytokines released in the periodontal infection may promote infection by respiratory pathogens by alteration of the respiratory epithelium [54].

P. GINGIVALIS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD):

Over the last two decades the association between periodontitis and COPD has been increasingly identified. Due to the anatomical position of oral cavity the bacteria can be easily carried to the lungs and cause seeding of the infection there [55]. COPD and periodontitis, both, are associated with inflammation and the destruction of the local connective tissue [56]. Poor oral hygiene contributes to increased mass and complexity of dental plaque, which may enhance bacterial interactions between innate plaque bacteria (*P. gingivalis*, *F. nucleate*) [5]. In a study by Madalli R et al by comparison between *P. gingivalis* from the sputum of COPD patients before and after oral prophylaxis showed a decline in the bacterial load [57]. Takahashi T et al [58] concluded from their study that *P. gingivalis*-related antibody titre could act as an autonomous factor for exacerbation tendency in COPD. Measurement of these titers can be a useful indicator for susceptibility to persistent exacerbations so as to formulate a treatment strategy for prevention of such exacerbations. [58].

P. GINGIVALIS AND ASTHMA

Although many studies have been conducted regarding periodontal and allergic diseases still it is not clear about the association between both. J W Card et al under took a study regarding modification of allergic airway inflammation in an established murine model of asthma by infection with the *P. gingivalis*. Their results indicated that *P. gingivalis* exerted differential regulatory effects on allergic airway inflammation that were dependent on relative to allergic sensitization. [59]. Arbes SJ Jr et al [60] investigated the relationship between

serum IgG levels to *A. actinomycetemcomitans* and *P. gingivalis* and asthma, wheeze, and hay fever. An inverse association was seen by them between *P. gingivalis* and the outcomes asthma, wheeze, and hay fever [60]. Study was conducted by [Roberto Rivera](#) and et al to make out the association between periodontitis and asthma among overweight adults. They found the subjects with severe periodontitis with asthma medication were less likely to have asthma, which strongly indicated an inverse association. (61)

P.GINGIVALISAND CNS:

Recently, periodontal pathogens are being linked with the neurodegenerative condition, Alzheimer's disease (AD), which is characterized by loss of memory. Even various clinical, epidemiological and molecular studies have shown that periodontitis has role with increased risk of dementia, including AD. An in vivo study in mice inoculated with *P. gingivalis* showed the evidence of *P. gingivalis* bacterial genomic DNA in the brain which was predicted to activate the complement cascade [62]. The Hajshengallis G et al[63] hypothesis explained that *P. gingivalis* may cause even the early development of a neurodegenerative condition. In their view, highly virulent strains of *P. gingivalis* access the CNS during healthy stages and only those individuals who are susceptible to inflammatory traits are likely to develop progressive inflammatory component representing neurodegenerative disease processes. [63] Thus, *P. gingivalis* at present may be a missing link in the process of infection driven inflammation which represents the early stage in the development of AD pathology along with appearance of hallmark proteins.

The study by Shapira L et al[96] shows that *P. gingivalis*, may have a role to play in the pathogenesis of CNS inflammatory disorders such as multiple sclerosis. *P. gingivalis* LPS induces the secretion of certain proinflammatory mediators by CNS glial cells. Injection of *P. gingivalis* into subcutaneous tissue in mice, along with experimental induction of autoimmune encephalomyelitis led to aggravation of the disease due to lymphocyte proliferation in the presence of encephalitogenic protein myelin basic protein [64].

CONCLUSION

The possible local persistent infections could exert systemic manifestations in a number of above mentioned ways. A good knowledge about the interactions between *P. gingivalis* and host cells at the cellular and molecular level therefore becomes necessary to improve the overall well-being of the host. So this compiled information accessible at this moment seems to justify that maintaining a good oral hygiene is not only important to prohibit oral diseases but also to support overall health of the individual.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

Abbreviations:

1. Base pair: bp
2. Guanine-cytosine: G-C
3. Transfer RNA: tRNA
4. Arg-gingipain: Rgp
5. Lys-gingipain: Kgp
6. Capsular polysaccharide: CPS
7. Tumor necrosis factor alpha: TNF- α
8. Monocyte chemoattractant protein-1 : MCP-1, Keratinocyte chemoattractant: KC, Macrophage inflammatory protein: MIP-2, regulated upon activation normal T cell expressed and secreted: RANTES
9. *Fusobacterium nucleate*: F.nucleatum
10. Matrix metalloproteinase-9: MMP-9
11. Signal transducer and activator of transcription 3: STAT-3
12. Janus kinase 2- JAK2, Glycogen synthase kinase 3 beta: GSK3 β
13. Nucleoside diphosphate kinase: NDK
14. Adenosine triphosphate: ATP
15. B-cell lymphoma 2: Bcl 2

16. MicroRNA: miRNA
17. Cyclin-dependant kinase: CDK
18. Polymerase chain reaction: PCR
19. Lipopolysaccharides: LPS
20. Prostaglandin E2: PGE2
21. C-reactive protein: CRP
22. Insulin receptor substrate-1: IRS-1
23. Bacteroidesforsythus: B.forsythus
24. Actinobacillusactinomycetemcomitans: A. actinomycetemcomitans
25. Preterm birth and low birth weight: PLBW
26. Heat shock proteins: HSP
27. Chronic obstructive pulmonary disease: COPD
28. The Third National Health and Nutrition Examination Survey: **NHANES III**
29. Alzheimer's disease: AD

REFERENCES

- [1] Nisengard RJ, Newman MG. Oral microbiology and immunology. 1994. Philadelphia, Saunders.
- [2] Bostanci N, Belibasakis GN. FEMS Microbiol Lett 2012; 333(1): 1-9.
- [3] Hajishengallis G, Lamont RJ. Mol Oral Microbiol 2012; 27(6): 409–419.
- [4] Parahitiyawa NB, Jin LJ, Leung WK, Yam WC, Samaranyakel LP. ClinMicrobiol Rev 2009; 22(1): 46–64.
- [5] Georgiou TO, Marshall RI, Barlod PM. Aust Dent J 2009; 49(4): 177–184.
- [6] Tezal M, Sullivan MA, Hyland A, Marshall JR, Stoler D, Reid ME et. Cancer Epidemiol Biomarkers Prev2009; 18(9): 2406-2412.
- [7] Van Winkelhoff AJ, Carlee AW, deGraaff J. Infect Immun 1985; 49(3): 494–497.
- [8] Vincents B, Guentsch A, Kostolowska D, von Pawel-Rammingen U, Eick S, Potempa J et al. FASEB J 2011; 25(10): 3741–3750.
- [9] D'Empaire G, Baer MT, Gibson FC. Infect Immun2011;74(11): 6236–6243.
- [10] Furuta N, Takeuchi H, Amano A. Infect Immun 2009; 77 (11): 4761–4770.<https://doi.org/10.1128/IAI.00841-09>
- [11] Tsuda K, Amano A, Umabayashi K, Inaba H, Nakaqawa I, Nakanishi Y et al. Cell StructFunct 2005; 30(2): 81–91.
- [12] Hajishengallis G, Wang M, Harokopakis E, Triantafilou M, Triantafilou K . Infect Immun 2006; 74(10): 5658–5666.
- [13] Whitmore SE, Lamont RJ. PLoSPathog 2014; 10(3):
- [14] Lamont RJ, Hajishengallis G. Trends Mol Med 2014; 21(3): 172-183.
- [15] Michaud DS. Carcinogenesis 2013; 34(10): 2193-2197.
- [16] Nagy KN, Sonkodi I, Szoke I, Nagy E, Newman HN. Oral Oncol 1998; 34(4): 304–308.
- [17] Binder GA, Fischman S, Revach B, Bulvik R, Maliutina A, Rubinstein AM et al . Oncotarget 2015; 6(26): 22613-22623.
- [18] Inaba H, Sugita H, Kuboniwa M, Iwai S, Hamada M, Noda T et al. Cell Microbiol 2014; 16(1): 131–45.
- [19] Li N, Grivennikov SI, Karin M. Cancer Cell 2011;19(4): 429–431.
- [20] Wang H, Zhou H, Duan X, Jotwani R, Vuddaraju H, Liang S et al. Infect Immun 2014; 82(10): 4118–4126.
- [21] Wang HH, Kumar A, Lamont RJ, Scott DA. Trends Microbiol 2014; 22(4): 208–217.
- [22] Morandini AC, Ramos-Junior ES, Potempa J, Nguyen KA, Oliveira AC, Bellio M et al. J Innate Immun 2014; 6(6): 831–845.
- [23] Mao S, Park Y, Hasegawa Y, Tribble GD, James CE, Handfield M et al. Cell Microbiol 2007; 9(8): 1997–2007.
- [24] Moffatt CE, Lamont RJ. Infect Immun 2011; 79(7): 2632–2637.
- [25] Homann N, Jousimies-Somer H, Jokelainen K, Heine R, Salaspuro M. Carcinogenesis 1997; 18(9): 1739–1743.
- [26] Salaspuro MP. Crit Rev Clin Lab Sci 2003; 40(2): 183–208.
- [27] Amar S, Han X. Med SciMonit2003; 9(12): 291-299.
- [28] Ford PJ, Gemmell E, Hamlet SM, Hasan A, Walker PJ, West MJ et al. Oral MicrobiolImmunol 2005; 20(5): 296-302.
- [29] Khlghatian M, Nassar H, Chou HH, Gibson FC 3rd, Genco CA. Infect Immun 2002; 70(1): 257–267.

- [30] Cairo F, Gaeta C, Dorigo W, Oggioni MR, Pratesi C, Pini Prato GP et al. *J Periodontal Res* 2004; 39(6): 442–446.
- [31] Herzberg MC, Meyer MW. *J Periodontol* 1996; 67(10): 1138–1142.
- [32] Deshpande RG, Khan MB, Genco CA. *Infect Immun* 1998; 66(11): 5337–5343.
- [33] Genco R J. *Cardiovasc Rev Rep* 1998, 19: 34–37.
- [34] Salvi GE, Carollo-Bittel B, Lang NP. *J. Clin. Periodontol* 2008; 35(8): 398–409.
- [35] Padmalatha G, Bavle RM, Satyakiran GVV, Paremala K, Sudhakara M, Makarla S. *JOMFP* 2016; 20(3): 413-418.
- [36] Ishikawa M, Yoshida K, Okamura H, Ochiai K, Takamura H, Fujiwara N et al. *BiochimBiophysActa* 2013; 1832(12): 2035-2043.
- [37] Taylor GW, Burt BA, Becker MP, Genco RJ, Shlossman M, Knowler WC et al. *J. Periodontol* 1996; 67(10): 1085–1093.
- [38] Demmer RT, Jacobs DR Jr., Desvarieux M. *Diabetes Care* 2008; 31(7): 1373–1379.
- [39] Makiura N, Ojima M, Kou Y, Furuta N, Okahashi N, Shizukuishi S et al. *Oral MicrobiolImmunol* 2008; 23(4): 348-51.
- [40] Liu R, Desta T, He H, Graves DT. *Endocrinology* 2004; 145(6): 2997–3003.
- [41] Leon R, Silva N, Ovalle A, Chaparro A, Ahumada A, Gajardo M et al. *J Periodontol* 2007; 78(7): 1249-1255.
- [42] Geerts SO, Nys M, De Mol P, Charpentier J, Albert A, Legrand V et al. *J Periodontol* 2002; 73(1): 73-78.
- [43] Offenbacher S, Jared HL, O'Reilly PG, Wells SR, Salvi GE, Lawrence HP et al. *Ann Periodontol* 1998; 3(1): 233-250.
- [44] Katz J, Chagini N, Shiverick KT, Lamont RJ. *J Dent Res* 2009; 88(6): 575-578.
- [45] James JL, Stone PR, Chamley LW. *HumReprod Update* 2006; 12(2): 137-144.
- [46] Hasegawa-Nakamura K, Tateishi F, Nakamura T, Nakajima Y, Kawamata K, Douchi T et al. *J Periodontol Res* 2006; 46(4): 497-504.
- [47] Dasanayake AP, Russell S, Boyd D, Madianos PN, Forster T, Hill E. *Dent Clin N Am* 2003; 47(1): 115–125.
- [48] Persson G R. Review of the literature. *J Oral Microbiol* 2012; 4: 11829
- [49] Wegner N, Wait R, Sroka A, Eick S, Nguyen KA, Lundberg K et al. *Arthritis Rheum* 2010; 62(9): 2662–2672.
- [50] Kinloch A, Lundberg K, Wait R, Wegner N, Lim NH, Zendman AJ et al. *Arthritis Rheum* 2008; 58(8): 2287–2295.
- [51] Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P et al. *Arthritis Rheum* 2008; 58(10): 3009–3019.
- [52] Mikuls TR, Payne JB, Reinhardt RA, Thiele GM, Marziarz E, Cannella AC et al. *IntImmunopharmacol.* 2009; 9(1): 38-42.
- [53] Martin T, Crouzier R, Weber JC, Kipps TJ, Pasquali JL. *J Immunol* 1994; 152(12): 5988-5996.
- [54] Scannapieco FA. *J Periodontol*1999; 70(7): 793–802.
- [55] Gomes-Filho IS, Passos JS, da Cruz SS. *J Oral Microbiol* 2010; 2: 10.
- [56] Usher AK, Stockley RA. *BMC Medicine* 2013;11: 241.
- [57] Madalli R, Kheur S, Reddy M, Kheur M, Mahalle A. *Dent Hypotheses* 2013; 7(3): 100-106.
- [58] Takahashi T, Muro S, Tanabe N, Terada K, Kiyokawa H, Sato S et al. *PLoS ONE* 2012; 7(7): e40570.
- [59] Card JW, Carey MA, Voltz JW, Alyce Bradbury, Catherine D. Ferguson. *Infection and immunity* 2010;78(6): 2488–2496 .
- [60] Arbes SJ Jr, Matsui EC. *J Allergy ClinImmunol*2012; 127(5): 1119-1127.
- [61] Rivera R, Andriankaja OM, Perez CM, Joshipura K. *Journal of clinical periodontology.* 2016;43(7):566-571.
- [62] Singhrao SK, Harding A, Poole S, Kesavalu L, Crean S. *Porphyromonas gingivalis Mediators of Inflammation* 2015: 137357.
- [63] Hajishengallis G, Darveau RP, Curtis MA. *Nat Rev Microbiol* 2012; 10(10): 717–725.
- [64] Shapira L, Ayalon S, Brenner T. *J Periodontol* 2002; 73(5): 511-6.